SCHEMBL15480604

SCHEMBL15480604

CN(c1ccc(C(=O)NO)cc1)S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
LMNA P02545 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
USP2 O75604 1/20 0.55
TP53 P04637 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
HDAC6 Q9UBN7 3/20 0.54
HDAC8 Q9BY41 2/20 0.54
HDAC3 O15379 1/20 0.54
FFAR1 O14842 1/20 0.53
MAPT P10636 3/20 0.52
HTT P42858 2/20 0.52
KDM4E B2RXH2 1/20 0.51
ALOX12 P18054 1/20 0.51
MCHR1 Q99705 1/20 0.50
HPGD P15428 2/20 0.49
ALDH1A1 P00352 1/20 0.49
GBA1 P04062 1/20 0.49
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15482262 0.88 HDAC6 (0.64) MEN1KMT2ALMNASMN1; SMN2HDAC6
SCHEMBL15480590 0.87 MAPT (0.68) MEN1KMT2ALMNASMN1; SMN2HDAC6
SCHEMBL15482278 0.87 LMNA (0.57) MEN1KMT2ALMNASMN1; SMN2HDAC6
SCHEMBL15480601 0.87 SIRT2 (0.56) MEN1KMT2ALMNASMN1; SMN2HDAC6
SCHEMBL15482232 0.86 MAPT (0.52) MEN1KMT2ALMNASMN1; SMN2HDAC6
SCHEMBL15480600 0.85 GBA1 (0.64) MEN1KMT2ALMNASMN1; SMN2HDAC8
SCHEMBL15480591 0.84 HDAC1 (0.61) MEN1KMT2ALMNASMN1; SMN2HDAC6
SCHEMBL664945 0.84 FFAR1 (0.61) MEN1KMT2ALMNASMN1; SMN2USP2
SCHEMBL15482244 0.83 HPGD (0.69) MEN1KMT2ALMNATP53MAPT
SCHEMBL15480598 0.83 HPGD (0.52) MEN1KMT2ALMNASMN1; SMN2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB (SE) 2021-03-04 US disclosed
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2017-01-26 US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 MEN1 4342/4885KMT2A 223/4885LMNA 489/4885
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 MEN1 4342/4885KMT2A 223/4885LMNA 489/4885
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 MEN1 4342/4885KMT2A 223/4885LMNA 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.